Aquestive Therapeutics (AQST) Earnings Analysis
Aquestive Therapeutics (AQST) next reports earnings on 2026-08-10, consensus EPS -0.1 USD. Last quarter (2026-03-04) it missed with EPS -0.26 USD vs -0.13 USD est (-100%). It has beaten estimates in 1/5 recent quarters (20%). Trailing P/E -6.46.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does AQST next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -0.1 USD |
| Revenue estimate | 0.01B |
AQST earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-04 | -0.26 USD | -0.13 USD | -100% | Miss |
| 2025-08-11 | -0.14 USD | -0.18 USD | +22.2% | Beat |
| 2025-05-12 | -0.24 USD | -0.17 USD | -41.2% | Miss |
| 2025-03-05 | -0.19 USD | -0.14 USD | -35.7% | Miss |
| 2024-11-04 | -0.13 USD | -0.12 USD | -8.3% | Miss |
Beat rate: 1/5 (20%) over reported quarters with consensus data.
AQST valuation and analyst view
| Trailing P/E | -6.46 |
|---|---|
| Trailing EPS | -0.56203 USD |
| Price / book | -14.19 |
| Dividend yield | 0.00% |
| Market cap | 0.39B |
| Analyst consensus | Buy (10 buy / 0 hold / 0 sell) |
| Avg price target | 10 USD |
Related research pages
Frequently asked questions
When is Aquestive Therapeutics (AQST)'s next earnings date?
Aquestive Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.1 USD and revenue estimate of 0.01B.
Did AQST beat earnings last quarter?
In its 2026-03-04 report, AQST posted EPS of -0.26 USD versus a -0.13 USD estimate — a miss of 100%.
What is AQST's earnings track record?
Over the last 5 reported quarters with consensus data, AQST beat estimates 1 times (20%).
What is AQST's current P/E ratio and EPS?
AQST trades at a trailing P/E of -6.46 on trailing EPS of -0.5620341147554896 USD.
What do analysts rate AQST?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 10 USD.